Adaptive Biotechnologies (NASDAQ:ADPT) Shares Break Above 50 Day Moving Average Following Insider Selling

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) passed above its 50 day moving average during trading on Wednesday following insider buying activity. The stock has a 50 day moving average of $26.37 and traded as high as $26.88. Adaptive Biotechnologies shares last traded at $26.71, with a volume of 2,326,040 shares.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ADPT shares. Morgan Stanley upped their price objective on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Monday, October 12th. BTIG Research raised their target price on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 29th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $30.06.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported earnings of $0.02 per share, versus analysts’ expectation of a $0.10-per-share loss. Management also said the company achieved total-company profitability ahead of expectations. Third-quarter 2026 financial results
• Positive Sentiment: Revenue was $83.9 million, exceeding the $71.57 million analyst estimate. Core measurable residual disease (MRD) revenue grew 44%, a strong growth signal for a key business area. Q3 earnings and revenues top estimates
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 trading plan and retained 377,802 shares. The planned nature of the sale may make it less meaningful as a signal about near-term business prospects. Insider share sale
• Negative Sentiment: Revenue was still down 10.7% from the year-ago quarter, tempering the strong results versus analyst estimates. The company also reported a negative net margin. Quarterly earnings report

Adaptive Biotechnologies Price Performance

The business’s fifty day moving average price is $26.37 and its 200 day moving average price is $19.76. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The stock has a market cap of $4.26 billion, a P/E ratio of -65.15 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $71.57 million. During the same period in the previous year, the firm posted $0.06 EPS. The firm’s revenue was down 10.7% on a year-over-year basis. Sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Adaptive Biotechnologies in the second quarter worth $324,735,000. Wellington Management Group LLP increased its holdings in Adaptive Biotechnologies by 53.2% in the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after purchasing an additional 2,053,944 shares during the period. Bank of America Corp DE bought a new position in Adaptive Biotechnologies during the 2nd quarter worth $37,109,000. Freestone Grove Partners LP bought a new position in Adaptive Biotechnologies during the 2nd quarter worth $18,912,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth about $16,858,000. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.